NAD+ Injection vs. Nasal Spray Programs

Direct answer

NAD+ injection and nasal-spray telehealth programs should be compared as different formulations and routes, not as the same product with different prices. Current provider catalogs show that one company can offer both routes at the same time, with different pricing, supply formats, and plan terms. RightFit therefore keeps route, formulation, price kind, billing period, provider services, and source attached to each program.

Current NAD+ programs tracked by formulation

Several providers currently offer both injection and nasal spray

The current RightFit catalog includes providers with both compounded NAD+ injection and compounded NAD+ nasal-spray programs. Effecty, Shed, 10Rx, and TRAVA are examples in the structured dataset. That overlap is useful because it shows that route-specific pricing is not only a comparison between different companies; the same provider can price and package the two routes differently.

RightFit does not use a provider-wide NAD+ price when the provider publishes multiple formulations. Each route receives its own provider-treatment record and price observation.

Shed currently separates injection, nasal, and oral NAD+ offers

Shed’s current NAD+ page lists separate compounded injection, nasal-spray, and oral options. The injection and oral options currently carry a higher standard starting amount than the nasal spray. Shed also runs promotional landing pages with first-month discounts, which is why the standard recurring price and temporary introductory price should not be merged.

That structure demonstrates two separate comparison dimensions at once: route and price type. A first-month nasal promotion should not replace the standard nasal rate, and neither nasal amount should be used as the price of the injection program.

Effecty also publishes route-specific NAD+ pricing

Effecty’s current treatment catalog lists an NAD+ injection and a separate NAD+ nasal spray. Its injection program has normal and longer-term plan pricing, while the nasal spray is listed separately. This is another reason a single provider-level NAD+ average can hide meaningful commercial differences.

TRAVA and 10Rx show that the two routes can be priced very closely

Not every provider creates a large price gap between injection and nasal spray. Current structured records for TRAVA and 10Rx place their injection and nasal programs much closer together than some other providers. That is why RightFit compares the actual provider-treatment rows instead of assuming that one route is always more expensive.

Price alone cannot establish equivalent supply

Two monthly-looking NAD+ prices can represent different formulations, concentrations, supply amounts, administration instructions, or package contents. RightFit therefore keeps supply duration and formulation details with the provider record when the source publishes them. A similar monthly price does not prove the products deliver an equivalent amount or experience.

Billing terms can change the apparent route comparison

Injection programs are especially likely to appear with multi-month discounts in the current dataset. A twelve-month injection rate can look lower than a month-to-month nasal price even though the customer must make a much longer commitment. RightFit keeps the standard rate and term-dependent effective rate separate so the route comparison is not distorted by commitment length.

Provider services can be bundled differently

Some NAD+ programs include provider evaluation, supplies, shipping, or ongoing support in the displayed amount. Others use a separate membership or subscription. Those inclusions can differ even when two programs use the same route. RightFit stores the service and fee structure separately from the medication amount.

Compounded status applies to both routes in the current tracked market

The injection and nasal-spray programs currently modeled in this comparison are compounded formulations. RightFit does not describe either route as an FDA-approved NAD+ drug and does not treat one compounded route as the approved reference product for the other.

Provider pages may use wellness language around energy, focus, aging, or cellular function. Those statements are provider marketing claims and are not used to determine the price, route ranking, or clinical value in this comparison.

FDA has issued specific sterile-compounding context for NAD+

FDA has warned compounders to use ingredients suitable for sterile compounding and specifically described food-grade NAD+ being used to make intravenous compounded products. FDA stated that food-grade ingredients are not suitable for sterile compounding without appropriate processing because of contamination and endotoxin risk, and it reported adverse events following use of NAD+ injectable drugs.

That warning is relevant context for sterile injectable compounding. It does not establish that every injectable NAD+ program has the problem FDA described, and it does not establish that a nasal formulation is safer. Provider-specific quality conclusions would require provider- or pharmacy-specific evidence.

Why the FDA warning does not create a route ranking

A regulatory warning about ingredient suitability in sterile compounding identifies a risk-control issue, not a comparative clinical trial between injection and nasal spray. RightFit can explain the warning while still avoiding the unsupported conclusion that one route is medically superior.

State availability should be verified by program

A provider’s ability to sell one NAD+ formulation in a state does not automatically prove that its other formulation is available there. Pharmacy coverage, provider licensure, and product-specific policies can differ. RightFit therefore uses program-level state evidence and leaves unverified combinations blank.

What to compare before interpreting the price

• Exact route: injection, nasal spray, or another formulation.
• Preparation type and compounded status.
• Normal recurring price.
• Promotional or multi-month effective price kept separately.
• Billing period and supply duration.
• Amount and term paid up front for prepaid plans.
• Required membership or subscription fee.
• Whether clinician review, supplies, and shipping are included.
• Program-level state availability when verified.
• Provider-primary source and last-verification date.

What RightFit will not infer

• A lower nasal price does not prove better value medically.
• A higher injection price does not prove a stronger or more effective product.
• Similar monthly prices do not prove equivalent concentration or supply.
• A provider offering both routes does not prove the routes are interchangeable.
• A general NAD+ wellness claim is not treated as evidence of route-specific effectiveness.
• The FDA sterile-compounding warning is not applied as a provider-specific accusation without evidence.

Why provider-specific source pages matter

A broad longevity catalog may say only that NAD+ is available, while the dedicated product page identifies the route, current amount, supply, and plan. RightFit favors the most specific current provider-owned page for each formulation and uses category or homepage language as secondary commercial context.

Promotions need their own records

Shed currently illustrates this well: its standard NAD+ page publishes recurring starting prices by formulation, while separate promotional landing pages advertise lower first-month amounts. Those are real offers, but they answer a different pricing question. RightFit should preserve the promotion without replacing the standard recurring rate.

Questions a reader can use

• Which NAD+ formulation is the provider actually prescribing?
• Is the displayed amount a standard price or an introductory offer?
• Does the lower price require a multi-month commitment?
• What is the supply period for the quoted amount?
• Are clinical care, supplies, and shipping included?
• Is a membership charged separately?
• Is this exact formulation available in the relevant state?
• Does the provider identify the dispensing or fulfillment pathway?
• When was the provider-owned source last checked?

What this comparison cannot decide

A commercial comparison cannot determine whether NAD+ treatment is appropriate for an individual or whether injection, nasal spray, or another route is preferable for that person. It also cannot turn provider marketing into evidence of clinical outcomes. Those questions are separate from the public price and program data.

Bottom line

NAD+ injection and nasal-spray programs overlap across several telehealth providers, but the routes differ in formulation, price structure, supply, and sometimes the services bundled with the program. Current provider pages from Shed, Effecty, TRAVA, 10Rx, and others show why route-specific records are necessary. RightFit keeps those commercial facts separate and adds FDA sterile-compounding context without using it to declare a clinical winner.

Why the cheapest displayed route can change by provider

Current provider data does not show one universal pricing relationship between injection and nasal spray. At some providers the nasal option is lower, while at others the two routes are priced much closer together. Multi-month injection discounts can also reverse a comparison that looks different at the ordinary monthly rate. That variability is evidence that route, provider, price type, and commitment all need to be considered together.

For that reason, RightFit does not publish a rule that nasal spray is always cheaper or injection is always more expensive. The live provider-treatment table is the better source for the current relationship.